This series of industry briefs takes an in-depth look at the transition of medicines from conventional, one-size-fits-all to targeted medicines, and how this transition is affecting the pharma services and diagnostics industry segments. We begin by quantitatively establishing the rapid transition of medicines from conventional to targeted medicines.
The Prism Doctrine
January 22, 2020
Disruption and Opportunity – The Abrupt Transition Toward Targeted Medicine
Built during the last century, the pharma services industry was primarily designed to develop, manufacture, distribute, and market conventional drugs. Such drugs have largely homogeneous logistical and economic
characteristics, resulting in the industry developing mass-production efficiencies through economies of scale. However, tomorrow’s ecosystem must allow for more specialized, complex treatments and patient journeys,
which will be tailored to each therapy in the case of stratified medicine, and to each patient with personalized medicine.